经皮采血检测C肽是1型糖尿病儿童和成人中微创、可靠的静脉采血替代方法
研究纳入91人(71例1型糖尿病,20例对照),同期采集静脉血和经皮毛细血管血(TCB)检测血浆C肽。TCB C肽与静脉血浆C肽一致性良好,检测静脉C肽≥200 pmol/L的敏感度和特异度均为100%,且TCB采血更受偏好;但TCB血浆检测胰岛自身抗体仍需进一步评估。
要点
- 经皮毛细血管采血检测C肽与静脉血浆一致性良好,平均差值0.008(95%CI -0.23~0.29)。
- TCB C肽检测静脉C肽≥200 pmol/L的敏感度100%(36/36)、特异度100%(50/50)。
- 1型糖尿病患者中63%偏好经皮采血 vs 7%偏好静脉采血,30%未决定。
核心结论
- 经皮毛细血管检测C肽是静脉采血的敏感、特异且可接受的替代方法;经皮采血检测胰岛自身抗体需进一步评估。
研究设计与样本
- 研究纳入91人(71例1型糖尿病,20例对照),同期采集静脉血和经皮毛细血管血(TCB)检测血浆C肽。
- 1型糖尿病患者中位年龄14.8岁(IQR 9.1-17.1),糖尿病病程4.0年(IQR 1.5-7.7);对照中位年龄42.2岁(IQR 38.0-52.1)。
- 1型糖尿病患者另提供静脉血清、静脉血浆和TCB血浆检测谷氨酸脱羧酶、胰岛抗原2和锌转运蛋白8自身抗体。
- 采用Bland-Altman比较TCB血浆与静脉血浆C肽水平一致性,并比较TCB血浆检测显著内源性胰岛素分泌(静脉C肽≥200 pmol/L)的能力。
- 采用既定阈值比较静脉血清与静脉血浆、TCB血浆检测自身抗体的能力,并通过适龄问卷评估可接受性。
主要发现
- 经皮采血平均耗时2.35分钟(SD 1.49),中位样本量50 µL(IQR 40-50),91例中3例(3.3%)失败,88例中13例(14.7%)样本量<35 µL。
- TCB C肽与静脉血浆一致性良好:静脉ln[C肽]减TCB ln[C肽]均值0.008,95%CI [-0.23, 0.29]。
- TCB C肽检测静脉C肽≥200 pmol/L的敏感度100%(36/36)、特异度100%(50/50)。
- 静脉血清多种自身抗体阳性时,TCB血浆一致22/32(敏感度69%),比较特异度35/36(97%)。
- TCB采血较静脉采血更受偏好:1型糖尿病患者中63% vs 7%偏好TCB,30%未决定。
关键数值与推荐
- 显著内源性胰岛素分泌定义为静脉C肽≥200 pmol/L,TCB C肽检测该阈值的敏感度100%(36/36)、特异度100%(50/50)。
- TCB血浆检测自身抗体与静脉血清比较:敏感度69%(22/32),特异度97%(35/36)。
- 经皮采血中位样本量50 µL(IQR 40-50),3.3%(3/91)失败,14.7%(13/88)样本量<35 µL。
临床怎么用
- 经皮毛细血管采血检测C肽可作为静脉采血的敏感、特异且可接受的替代方法。
- 经皮采血检测胰岛自身抗体需进一步评估。
局限性
- 经皮采血检测胰岛自身抗体需进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: C-peptide and islet autoantibodies are key type 1 diabetes biomarkers, typically requiring venous sampling, which limits their utility. We assessed transdermal capillary blood (TCB) collection as a practical alternative. RESEARCH DESIGN AND METHODS: Ninety-one individuals (71 with type 1 diabetes, 20 control; individuals with type 1 diabetes: aged median 14.8 years [interquartile range (IQR) 9.1-17.1], diabetes duration 4.0 years [1.5-7.7]; control individuals: 42.2 years [38.0-52.1]) underwent contemporaneous venous and TCB sampling for measurement of plasma C-peptide. Participants with type 1 diabetes also provided venous serum and plasma, and TCB plasma for measurement of autoantibodies to glutamate decarboxylase, islet antigen-2, and zinc transporter 8. The ability of TCB plasma to detect significant endogenous insulin secretion (venous C-peptide ≥200 pmol/L) was compared along with agreement in levels, using Bland-Altman. Venous serum was compared with venous and TCB plasma for detection of autoantibodies, using established thresholds. Acceptability was assessed by age-appropriate questionnaire. RESULTS: Transdermal sampling took a mean of 2.35 min (SD 1.49). Median sample volume was 50 µL (IQR 40-50) with 3 of 91 (3.3%) failures, and 13 of 88 (14.7%) <35 µL. TCB C-peptide showed good agreement with venous plasma (mean venous ln[C-peptide] - TCB ln[C-peptide] = 0.008, 95% CI [-0.23, 0.29], with 100% [36 of 36] sensitivity/100% [50 of 50] specificity to detect venous C-peptide ≥200 pmol/L). Where venous serum in multiple autoantibody positive TCB plasma agreed in 22 of 32 (sensitivity 69%), comparative specificity was 35 of 36 (97%). TCB was preferred to venous sampling (type 1 diabetes: 63% vs. 7%; 30% undecided). CONCLUSIONS: Transdermal capillary testing for C-peptide is a sensitive, specific, and acceptable alternative to venous sampling; TCB sampling for islet autoantibodies needs further assessment.
引用
- Besser REJ, Long AE, Owen KR, et al. Transdermal Blood Sampling for C-Peptide Is a Minimally Invasive, Reliable Alternative to Venous Sampling in Children and Adults With Type 1 Diabetes. Diabetes Care. 2024. PMID: 38087932. doi:10.2337/dc23-1379
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。